Discover how AstraZeneca has turned around its fortunes
It is 10 years since the board of AstraZeneca (AZN) rejected a cash and share takeover proposal from US rival Pfizer (PFE:NYSE) worth £53.50 per share on the grounds the price did not reflect the true value of the business.Since rejecting the offer, AstraZeneca's shares have appreciated three-fold while Pfizer's shares are trading 5% below where they were trading a decade ago.Credit must be given